Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endothelial Protocol in Critically Ill COVID-19
NCT04813471Phase 3Unknown
- Sponsor
- LAU Medical Center-Rizk Hospital
- Start
- Jan 2021
- Primary completion
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of atorvastatin, nicorandil, arginine, folic acid, Compound Vitamin B in coronavirus disease 2019 (COVID-19), endothelial dysfunction, sponsored by LAU Medical Center-Rizk Hospital. Status: unknown.
02
Drugs
atorvastatinnicorandilargininefolic acidCompound Vitamin B
03
Conditions
coronavirus disease 2019 (COVID-19)endothelial dysfunction
Beyond the preview
Go deeper on NCT04813471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04813471.